

**Initial Results from
Ongoing Dose-Escalation
Study of XmAb819 &
Oncology Pipeline Update**

October 24, 2025



Forward-Looking Statements


Certain statements contained in this presentation, other than statements of historical fact, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Xencor's development plans and timelines; potential regulatory actions; expected use of cash resources; the timing and results of clinical trials; the plans and objectives of management for future operations; and the potential markets for Xencor's product and development candidates. Forward-looking statements are based on the current expectations of management and upon what management believes to be reasonable assumptions based on information currently available to it, and involve numerous risks and uncertainties, many of which are beyond Xencor's control. These risks and uncertainties could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, but are not limited to, potential delays in development timelines or negative preclinical or clinical trial results, reliance on third parties for development efforts and changes in the competitive landscape including changes in the standard of care for treatment of diseases for which we are developing product candidates, as well as other risks described in Xencor's filings with the Securities and Exchange Commission. Xencor expressly disclaims any duty, obligation or undertaking to update or revise any forward-looking statements contained herein to reflect any change in Xencor's expectations with regard thereto of any subsequent change in events, conditions or circumstances on which any such statements are based, except in accordance with applicable securities laws. For all forward-looking statements, we claim the protection of the safe harbor for forward looking statements contained in the Private Securities Litigation Reform Act of 1995.

Disclaimer: We use our trademarks and our logo in this presentation. This presentation also includes trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, trademarks and tradenames referred to in this presentation appear without the “®” and “TM” symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and tradenames.

Proven Power of XmAb® Engineering: Proteins By Design®

Small changes, big functional impacts

- XmAb Fc Domains augment native immune functions in molecules and/or control their structure, while preserving desired attributes
- XmAb engineered antibodies are designed to solve complex biologic problems
- Strong patent portfolio



**RATIONALLY ENGINEERED
XMAB DRUG CANDIDATES**

TCE T-cell engager ccRCC clear cell renal cell carcinoma
GCT germ cell tumor RA rheumatoid arthritis UC ulcerative colitis


Advancing an optimized portfolio of XmAb drug candidates

Oncology: Advancing a portfolio novel TCEs


- **XmAb819** (ENPP3xCD3) in advanced ccRCC: enrolling first Phase 1 dose expansion cohort
- **XmAb541** (CLDN6xCD3) in ovarian cancer and GCTs: ongoing Phase 1 dose escalation

Autoimmune: anti-TL1A and CD3 B-cell depletion

- **XmAb942** (TL1A): XENITH-UC 2b study ongoing
- **XmAb412** (TL1A x IL23p19): Ph1 to initiate in 2026
- **Plamotamab** (CD20xCD3): Ph1 RA study ongoing
- **XmAb657** (CD19xCD3): Ph 1 to initiate in 4Q'25



XmAb
Bispecific TCEs



**Xtend™ Antibodies with Potential
Best-in-class Half-life Extension**

Partnerships leverage modular XmAb technology

- More than 15 technology license partnerships greatly broadens scope with little-to-no effort
- Multiple commercialized XmAb antibodies

ULTOMIRIS®

MONJUVI®/MINJUVI®

COLLABORATION PORTFOLIO INCLUDES

Johnson & Johnson
Innovative Medicine

AMGEN

ALEXION
AstraZeneca Rare Disease

Incyte

Genentech
A Member of the Roche Group

GILEAD

VIR

astellas

Registered trademarks: Ultomiris® (Alexion Pharmaceuticals, Inc.),
Monjuvi® & Minjuvi® (Incyte Holdings Corp.)

Next-Gen XmAb[®] Drug Design in Oncology & Autoimmune Diseases

Pipeline focus on T-cell engagers and bispecific mechanisms

Program	Targets	XmAb [®] Platforms	Indications	Discovery	Preclinical	Phase 1	Phase 2	Phase 3
---------	---------	-----------------------------	-------------	-----------	-------------	---------	---------	---------

Solid Tumor Oncology: T-cell Engagers (CD3 & CD28)

XmAb819	ENPP3 x CD3	2+1 Bispecific	ccRCC					
XmAb541	CLDN6 x CD3	2+1 Bispecific, Xtend™	Ovarian cancer, GCT, oncology					
XmAb808	B7-H3 x CD28	2+1 Bispecific, Xtend	Prostate cancer, oncology					
XmAb Program	Undisclosed TCE	Bispecific, Xtend	Solid tumor oncology					

Immunology Programs (TL1A & CD3 B-Cell Depletion)

XmAb942	TL1A	Xtend, FcKO	IBD (Ulcerative colitis)			Phase 2b XENITH-UC		
XmAb412	TL1A x IL23p19	Bispecific, Xtend	IBD			2026		
Plamotamab	CD20 x CD3	Bispecific	Rheumatoid Arthritis			Phase 1b		
XmAb657	CD19 x CD3	2+1 Bispecific, Xtend	Autoimmune Diseases			2H'25		

Key

Solid tumors


Immunology

Planned Study Initiation

ccRCC clear cell renal cell carcinoma GCT germ cell tumors FcKO Fc knock out IBD Inflammatory bowel disease


XmAb819: ENPP3 x CD3 T-cell Engager in Development for ccRCC

XmAb819 engages the immune system and activates T cells for highly potent and targeted lysis of tumor cells expressing ENPP3



ENPP3 *Ectonucleotide pyrophosphatase / phosphodiesterase family member 3*


A differentially expressed target, with high level expression in renal cell carcinoma and low-level expression on normal tissues¹



XmAb[®] 2+1

Enables antibodies to bind more avidly and selectively kill tumor cells with higher antigen density, potentially sparing normal cells


Selective T-cell directed cytotoxicity for cells with ENPP3 expression





¹ Doñate, Fernando, et al. Clinical Cancer Research 22.8 (2016)

2+1 Bispecifics: XmAb® T Cell Engagers Use Multiple Formats and Affinity Designs to Customize for Each Tumor Target

High expressing tumor cell



Low expressing normal cell



Examples of XmAb 2+1 TCEs: xaluritamig (STEAP1), ASP2138 (CLDN18.2), XmAb819 (ENPP3), XmAb541 (CLDN6)

Ongoing Phase 1 Dose-Escalation of XmAb819 in ccRCC



Initial Results

Data Cut-off: September 19, 2025




XmAb819 Phase 1 Dose Escalation: Parallel IV and SC Design

Study Schema and Dosing Schedule



TD Target Dose CPI checkpoint inhibitor

Pharmacokinetic Profile of XmAb819 Supports QW - Q2W Dosing



Parameter	Value
Half-life	8.7 Days
Subcutaneous Administration	
T _{max}	5.5 Days
Absolute Bioavailability	55-70%

Steady state drug concentrations attained in Cohorts 9 and 10 fall within the PK target dose range expected to achieve anti-tumor activity

Heavily Pre-treated Patient Population in Ongoing Dose Escalation

Baseline Characteristics	
N	69
Median age, Years (Min, Max)	60 (34, 77)
Male, n (%)	55 (80)
Race, n (%)	
White	61 (88)
Other	8 (12)
Time since initial diagnosis, Months (Min, Max)	53.6 (8, 259)
IDMC risk score at initial diagnosis, n (%)	
Favorable	22 (32)
Intermediate	19 (28)
Poor	9 (13)
Not Available	19 (28)
Sarcomatoid features, n (%)	7 (10)

Prior Therapy	
N	69
# Prior regimens, Median (Min, Max)	4 (1, 8)
1, n (%)	5 (7)
2	16 (23)
3	13 (19)
4	9 (13)
≥5	26 (38)
Prior treatments, n (%)	
Checkpoint inhibitor	69 (100)
VEGF TKI	69 (100)
2 or more TKI	42 (61)
HIF2α inhibitor	25 (36)
Prior Nephrectomy, n (%)	47 (68)

Low Rate of Discontinuations Due to Adverse Events

Patient Disposition	
N	69
Treatment Status, n (%)	
Ongoing	17 (25)
Discontinued	52 (75)
Reason for Treatment Discontinuation, n (%)	
Adverse event*	3 (4)
Physician decision	3 (4)
Subject declines further treatment	2 (3)
Progressive disease	38 (55)
Clinical progression	6 (9)

* Elevated liver enzymes (n=1), non-fatal myocardial infarction in the presence of hypotension and CRS (n=1), AST/ALT increased (n=1)

Safety Summary – Well-tolerated Treatment With >90% of Patients Reaching Target Dose; Low Rate of Discontinuation

Treatment Emergent Adverse Events (TEAE), n (%)	
N	68 (99)
Grade ≥3	48 (70)
Related Grade ≥3	31 (45)
Serious TEAE	35 (51)
Related Serious TEAE	28 (41)
Lead to Dose Reduction	4 (6)
Did Not Reach Target Dose	6 (9)
Lead to Treatment Discontinuation	3 (4)
Lead to Death	0

CRS Profile Primarily Low Grade and Occurs in Initial Priming Doses


Correct dose preparation resulted in 4% Grade 3 CRS (2/51), whereas dose preparation errors resulted in 28% Grade 3 CRS (5/18)

In the target dose range, correct dose preparation resulted in 6% Grade 3 CRS (1/18), whereas dose preparation errors resulted in 50% Grade 3 CRS (3/6)


- Port and syringe errors diluting XmAb819 drug product during the priming dose preparation led to higher drug exposure (3-8x) in some patients after the priming dose
- Errors correlated to Grade 3 CRS and step-up dosing delays
- Mitigation through site retraining completed

**Eliminating root cause of multiple dilution steps
with low concentration drug product
rollout in 1H 2026**

**Rate and Severity of CRS
Overall Population (n=69)**




**Rate and Severity of CRS
Target Dose Range (n=24)**




AEs Primarily During the Priming Period and Well Managed With Low Overall Rate at Target Doses

**Overall TEAE and Related TEAE
by Maximum Severity Grade (N=69)**



**>Day 29 to End of Study TEAE and Related TEAE
by Maximum Severity Grade (N=69)**




Most common AEs are CRS and rash

- Majority of CRS events are Grade 1/2 and occur during priming
- Rash events are mostly Grade 1/2; responsive to antihistamines and steroids (topical/oral)

Clear Evidence of XmAb819 Dose Response in Ongoing Dose Escalation of Heavily Pre-Treated Patients


Best Percent Change from Baseline in Tumor Lesion (RECIST 1.1)

Low Dose Cohorts (N=38)*



* Excludes 4 patients without post-baseline scans and 3 patients with non-evaluable post-baseline measurements

Target Dose Cohorts (N=20)†



† Excludes 3 patients without post-baseline scans and 1 patient with non-evaluable post-baseline measurements

‡ PD at first scan (D48) prior to receiving target dose on D50. Continued treatment post-progression resulted in 47% tumor reduction. Continues on study at week 30.

Best Overall Response Supports Monotherapy Development


All Responders Treatment Ongoing

Best Overall Response in the Efficacy Evaluable Target Dose Range	
N	20*
Objective Response Rate (ORR), % (95% CI)	25% (9, 49)
Complete Response (CR)	0
Unconfirmed Partial Response (uPR) / Confirmed Partial Response (cPR) [†] , n (%)	5 (25)
Stable Disease (SD), n (%)	9 (45)
Disease Control Rate (DCR), % (95% CI)	70% (46, 88)


* Excludes 3 patients without post-baseline scans and 1 patient with non-evaluable post-baseline measurements.

† 4 cPR. 1 uPR deemed not evaluable after PR (54% reduction in target lesions at week 12) due to subsequent radiation to symptomatic non-target lesion with target lesion in field. The patient continues on treatment with stable scan at week 36.

Percent Change from Baseline in Tumor Lesion
Responders in Target Dose Range




Majority of Patients Experience Reduction in Tumor Lesions



Corrected Excludes 3 patients without post-baseline scans and 1 patient with non-evaluable post-baseline measurements

XmAb819 Treatment Has Resulted in Sustained Disease Control

Response by Subject, Efficacy Evaluable (RECIST 1.1)
Target Dose Range (N=20)




Corrected

† PD at first scan (D48) prior to receiving target dose on D50. Continued treatment post-progression resulted in a 47% tumor reduction.

Case Example: ~63% Target Lesion Reduction Despite Membrane TPS<25% Indicates Potential Bystander Effect


- 56-year-old male diagnosed ~10 years ago; metastatic disease less than 5 years ago
- 2 prior lines of therapy: cabozantinib/nivolumab (1 month), lenvatinib/everolimus (3 years)



- Membrane ENPP3+ in <25% tumor
- Diffuse cytoplasmic staining


Baseline CT Scan

**Baseline target lesion
(28 x 26mm)**



Post-treatment CT Scan

**Decrease in
target lesion (11 x 8mm)**



Competitive Positioning & Commercial Opportunity



XmAb819 On-track for ccRCC Pivotal Study Start During 2027

Achieved 25% ORR in unselected, heavily pretreated ccRCC patients, meeting internal criteria for progression to dose-expansion phase



Well-tolerated safety profile observed with mainly Grade 1/2 CRS, transient rash and liver enzyme elevations, no ICANS; patients beyond Day 29 show low incidence of mild AEs



Enrollment at IV Expansion Dose 1 has initiated; dose escalation continues to identify IV Expansion Dose 2




Determination of optimal IV or SC administration route and RP3D decision




Expansion into additional tumor types and combination studies with existing SoC in ccRCC, following establishment of the monotherapy RP3D



Size of Global RCC Market Expected to Reach ~\$12B in 2030 With Limited 2L+ Treatment Options Beyond VEGF-TKI¹



U.S. Total Addressable Market (TAM) in RCC in 2025





Aggregate U.S. Net Sales of Cabometyx[®] + Lenvima[®] + Welireg[®] in RCC^{1,2}

¹ GlobalData ² Company earnings reports
Registered trademarks: Cabometyx (Exelixis, Inc.), Lenvima (Eisai R&D Management Co., Ltd.), Keytruda & Welireg (Merck Sharp & Dohme LLC), Opdivo (Bristol-Myers Squibb Company)

Opportunity for a Novel First-in-class T-cell Engager to Improve SoC for Patients With Advanced ccRCC


US ccRCC incidence
~ 60k¹ new cases
per year

Global Incidence²: ~435k/year



¹ SEER ² GLOBOCAN 2022 ³ Ozay ZI et al. Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the US. JAMA Netw Open.
SoC standard of care Nivo nivolumab Ipi ipilimumab Pembro pembrolizumab Lenva lenvatinib

Evolving ccRCC Landscape Has Opportunity to Redefine SoC with XmAb819 in 2L+ Post IO and VEGF-TKI Treatment



¹ Choueiri, et al. Nature medicine 27.5 (2021): 802-805. ² ESMO 2023 Presentation from Dr. Albiges. ³ Rini, et al. The Lancet Oncology 21.1 (2020): 95-104.

XmAb819 Preliminary Efficacy Demonstrates Potential to Advance SoC for Patients That Have Progressed After CPI and VEGF-TKI Treatment


Drug	XmAb819	Belzutifan	Belzutifan	Tivozanib
Study	Preliminary Dose Escalation	Phase 1 Dose Expansion (ccRCC) ¹	IA1 & IA2 for LITESPARK-005 ²	TIVO-3 Study ³
Efficacy Evaluable, N	20	55	374	175
Overall Response Rate (ORR), % (95% CI)	25% (9-49)	25% (15-39)	23% (19-27)	18% (12-24)
Complete Response (CR)	0%	0%	4%	0%
Partial Response (PR)	25%	25%	19%	18%
Stable Disease (SD)	45%	54%	38%	55%
Disease Control Rate (DCR)	70%	80%	61%	73%
Baseline Characteristics, N	69	55	374	175
Prior Regimens, Median (Range)	4 (1-8)	3 (1-9)	2 (1-4)	2 (2-3)
1, %	7%	15%	12%	0%
2	23%	24%	42%	62%
≥3 prior regimens	70%	62%	45%	38%
3	19%	≥3 prior 62%	45%	38%
4	13%	NA	1%	0%
≥5	38%	NA	0%	0%
Prior treatments, %				
Checkpoint inhibitor	100%	80%	100%	27%
VEGF TKI	100%	91%	100%	100%
2 or more TKI	61%	NA	50%	45%
HIF2α inhibitor	36%	0%	0%	0%

¹ Choueiri, et al. Nature medicine 27.5 (2021): 802-805. ² ESMO 2023 Presentation from Dr. Albiges. ³ Rini, et al. The Lancet Oncology 21.1 (2020): 95-104.

Strategic Expansion Opportunities for XmAb819 Beyond ccRCC

ENPP3+ patients in 2L/3L+ setting¹ of pRCC, CRC & NSCLC

~60K



Papillary RCC

Standard of care
Cabozantinib

Treatable patients

~6K



MSS Colorectal Cancer

Standard of care
**Regorafenib or Fruquitinib
or FTD/TPI + Bevacizumab**

Treatable patients

~13K



**NSCLC
Adenocarcinoma**

Standard of care
Docetaxel

Treatable patients

~40K




¹ Estimates for U.S. 2025 ENPP3 population based upon H-Score of ≥ 1

MSS microsatellite stable **NSCLC** non-small cell lung cancer

Early Look at XmAb541 in Advanced Ovarian Cancer, Endometrial Cancer and Germ Cell Tumors




XmAb[®]541: CD3 T-cell Engager for Ovarian Cancer & Solid Tumors

XmAb 2+1 Design	XmAb541 (CLDN6 x CD3)	Phase 1 Dose Escalation Study
 anti-CLDN6 2 Fabs anti-CD3 1 scFv Xtend™ Bispecific Fc Domain	Highly selective for CLDN6 over CLDN9  MFI (AF647) Conc. (ng/mL) - CLDN6 - CLDN9 - CLDN3 - CLDN4 - CLDN8 - CLDN17 - Differential expression in cancerous tissue presents CLDN6 as an intriguing target - CLDN family members, which are small membrane proteins, have high sequence identity, complicating antibody design - XmAb541 engineered for CLDN6 selectivity over similar CLDN9, CLDN3 and CLDN4	- Ongoing Phase 1 study, initiated in 1H24 - Enrolling patients with ovarian, endometrial and germ cell tumors - CLDN6 CDx pre-screening for patients with ovarian and endometrial cancers, but not required for GCT Representative IHC from enrollment  GCT Endometrial Ovarian NCT06276491

GCT germ cell tumor MFI mean fluorescence intensity CDx companion diagnostic IHC immunohistochemistry

XmAb541 Best Overall Response at Most Recently Evaluated IV Dose Level



Data cut-off: October 1, 2025 Ova ovarian cancer End endometrial cancer GCT germ cell tumor Per peritoneal cancer PR partial response SD stable disease PD progressive disease

Market Opportunity for Xmab541 in CLDN6+ Gynecological Tumors


	Epidemiology	SoC Per Line of Therapy	Commercial Opportunity
Ovarian Cancer CLDN6 positivity: ~50-60% ¹	20k New U.S. cases/yr 1 LoT: 15k 2 LoT: 12k	Chemo ± bev ± PARPi Chemo ± bev, mirv (FRα+)	 Total sales in 1H25: \$338 million ² Global TAM by 2030: ~4.5 \$bn ³
Endometrial Cancer CLDN6 positivity: ~13-20% ¹	65k New U.S. cases/yr 1 LoT: 15k 2 LoT: 7k	Chemo + PD-1 therapies Chemo + PD-1 therapies	 Total sales in 1H25: \$196 million ² Global TAM by 2030: ~4.5 \$bn ³
Germ Cell Tumors CLDN6 positivity: ~80-90% ⁴	10k New U.S. cases/yr 1 LoT: 3k 2 LoT: 1k	Platinum-based chemo Chemo ± autologous transplant	 Approved drugs Global TAM by 2035: ~4.2 \$bn ⁵

1 Xencor internal data 2 Q2 2025 Company earnings 3 GlobalData 4 Clin Cancer Res (2023) 29 (11): 2131–2143 5 IMARC Group LoT line of therapy TAM total addressable market

Closing Remarks



Building a Fully Integrated Oncology Company on Novel TCEs



TCE T-cell engager PoC Proof of concept DE dose escalation RP3D recommended Phase 3 dose ccRCC clear cell renal cell carcinoma
FIH first-in-human MSD mid-single digit HSD high-single digit DD double digit GEJ gastroesophageal junction

**Initial Results from
Ongoing Dose-Escalation
Study of XmAb819 &
Oncology Pipeline Update**

October 24, 2025

